株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

肺気腫:パイプライン製品の分析

Emphysema - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 200444
出版日 ページ情報 英文 48 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
肺気腫:パイプライン製品の分析 Emphysema - Pipeline Review, H2 2016
出版日: 2016年09月30日 ページ情報: 英文 48 Pages
概要

肺気腫は長期的・進行性の肺疾患です。その特徴として、肺胞(肺内部の気嚢)の過膨張による息切れなどが挙げられます。この疾患の場合、ガス交換(酸素と二酸化炭素)に関わる肺組織が破壊されるため、肺胞の外へのガスの動きが緩慢化または停止し、呼気の流れが遅くなるか止まってしまいます。また、肺気腫は慢性閉塞性肺疾患(COPD)の一種でもあります。喫煙が肺気腫の一般的な原因となっています。治療法には吸入器、酸素、薬物治療、また時として外科手術による症状緩和などが挙げられます。

当レポートでは、世界各国での肺気腫治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査しています。

イントロダクション

  • 調査範囲

肺気腫の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

肺気腫:企業で開発中の治療薬

肺気腫:大学/機関で研究中の治療薬

肺気腫:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

肺気腫:企業で開発中の製品

肺気腫:大学/機関で研究中の製品

肺気腫の治療薬開発に従事している企業

  • Abeona Therapeutics, Inc.
  • Angion Biomedica Corp.
  • ProMetic Life Sciences Inc.
  • rEVO Biologics, Inc.

肺気腫:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

肺気腫:最近のパイプライン動向

肺気腫:休止中のプロジェクト

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8515IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Emphysema - Pipeline Review, H2 2016, provides an overview of the Emphysema (Respiratory) pipeline landscape.

Emphysema is a type of COPD involving damage to the alveoli in the lungs. Symptoms include shortness of breath and cough with sputum. Risk factors include age, smoking, exposure to air pollutions, factory fumes, coal and silica dust. Treatment includes bronchodilators, antibiotics and steroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Emphysema - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Emphysema (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Emphysema (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Emphysema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 8 and 1 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively for Emphysema.

Emphysema (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Emphysema (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Emphysema (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Emphysema (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Emphysema (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Emphysema (Respiratory)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Emphysema (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Emphysema (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Emphysema Overview
  • Therapeutics Development
    • Pipeline Products for Emphysema - Overview
    • Pipeline Products for Emphysema - Comparative Analysis
  • Emphysema - Therapeutics under Development by Companies
  • Emphysema - Therapeutics under Investigation by Universities/Institutes
  • Emphysema - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Emphysema - Products under Development by Companies
  • Emphysema - Products under Investigation by Universities/Institutes
  • Emphysema - Companies Involved in Therapeutics Development
    • Angion Biomedica Corp.
    • ProMetic Life Sciences Inc.
    • rEVO Biologics, Inc.
    • SATT North SAS
    • TGV-Laboratories
  • Emphysema - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • alpha-1 proteinase inhibitor (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alpha-1 proteinase inhibitor (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibody for Emphysema - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BB-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EDO-66 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MG-53 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit EMAP II for Emphysema - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Mul-1867 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Inhibit Beta Galactosidase for Pulmonary Emphysema - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Human Alpha-1 Antitrypsin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TM-5441 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Emphysema - Dormant Projects
  • Emphysema - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Emphysema, H2 2016
  • Number of Products under Development for Emphysema - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Emphysema - Pipeline by Abeona Therapeutics, Inc. , H2 2016
  • Emphysema - Pipeline by Angion Biomedica Corp., H2 2016
  • Emphysema - Pipeline by ProMetic Life Sciences Inc., H2 2016
  • Emphysema - Pipeline by rEVO Biologics, Inc., H2 2016
  • Emphysema - Pipeline by SATT North SAS, H2 2016
  • Emphysema - Pipeline by TGV-Laboratories, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Emphysema - Dormant Projects, H2 2016
  • Emphysema - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Emphysema, H2 2016
  • Number of Products under Development for Emphysema - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top